Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Fig. 4

Common adverse events. Common adverse events in patients treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab) are shown. The percentages of grade III or IV adverse events for both treatments are shown. The figures in parenthesis are the percentages of grade I or II adverse events

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us